ArticleScientific reports2026
Japanese cancer survivors have a higher risk of fragility fractures over ten years.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to clarify the risk of fragility fractures (FFs) in Japanese cancer survivors compared with individuals without cancer by incorporating time-dependent variables. In a 10-year cohort of 10,330 adults aged 40–69 years, we assessed the risk of FFs (i.e., hip, vertebral compression, and distal radius fractures) associated with cancer status by using time-dependent Cox proportional hazards analyses. The models were adjusted for demographic, lifestyle, and medical factors. The time-dependent variables included cancer status and age. Analyses were performed according to cancer treatment status, number of primary cancers, and cancer site. Among the 10,330 participants (mean age, 56.4 years; females, 6148), 386 experienced FFs. Compared with participants without cancer, a higher risk of overall FFs was observed in participants with cancer (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.03–1.89). This risk was further elevated among participants with active cancer (HR, 1.71; 95% CI, 1.15–2.55), multiple primary cancers (HR, 1.42; 95% CI, 1.04–1.95), stomach cancer (HR, 1.84; 95% CI, 1.01–3.37), kidney cancer (HR, 3.74; 95% CI, 1.20–11.70), and hematologic cancer (HR, 7.70; 95% CI, 2.45–24.16). These findings highlight the importance of FF prevention strategies in cancer survivorship care in aging Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.